Literature DB >> 19447494

Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression.

Alyson K Baker1, Ruipeng Wang, Nigel Mackman, James P Luyendyk.   

Abstract

Bacterial lipopolysaccharide (LPS) induces monocytes/macrophages to express proinflammatory cytokines and tissue factor (TF), the primary activator of the coagulation cascade. Anti-inflammatory signaling pathways including the phosphatidylinositol-3-kinase (PI3K)-Akt pathway inhibit proinflammatory and TF gene expression in macrophages. We determined the role of Akt, the mammalian target of rapamycin (mTOR) and interleukin-10 in the inhibition of LPS-induced proinflammatory cytokine and TF gene expression in peritoneal macrophages (PMs). We used wild type (WT) peritoneal macrophages (PMs), and PMs from PTEN(flox/flox)/LysMCre mice (PTEN(-/-) PMs), which have increased Akt activity. Pharmacologic inhibition of mTOR with rapamycin inhibited LPS induction of IL-10 mRNA and protein, and enhanced the expression of TF and the proinflammatory cytokine TNFalpha in WT PMs. Furthermore, neutralizing IL-10 with anti-IL-10 antibody enhanced LPS induction of TNFalpha and TF expression in WT PMs. The addition of recombinant IL-10 abolished rapamycin enhancement of LPS-induced TNFalpha and TF expression in WT PMs. Consistent with enhanced Akt activation, LPS-induced IL-10 expression was increased in PTEN(-/-) PMs compared to WT PMs. In contrast, LPS-induced TNFalpha and TF expression was significantly reduced in PTEN(-/-) PMs compared to WT PMs. However, the neutralizing IL-10 antibody did not completely prevent inhibition of LPS-induced TNFalpha and TF expression in PTEN(-/-) PMs. The results indicate that mTOR dependent IL-10 expression leads to inhibition of LPS induction of TF and the proinflammatory cytokine TNFalpha in WT macrophages. In contrast, the decrease in LPS-induced TNFalpha and TF expression in PTEN(-/-) PMs also requires an IL-10-independent pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447494      PMCID: PMC2699995          DOI: 10.1016/j.molimm.2009.04.011

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  38 in total

1.  Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.

Authors:  C Rommel; B A Clarke; S Zimmermann; L Nuñez; R Rossman; K Reid; K Moelling; G D Yancopoulos; D J Glass
Journal:  Science       Date:  1999-11-26       Impact factor: 47.728

2.  The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages.

Authors:  W Ma; W Lim; K Gee; S Aucoin; D Nandan; M Kozlowski; F Diaz-Mitoma; A Kumar
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

3.  Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1.

Authors:  A H Kim; G Khursigara; X Sun; T F Franke; M V Chao
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

4.  Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia.

Authors:  D Pajkrt; T van der Poll; M Levi; D L Cutler; M B Affrime; A van den Ende; J W ten Cate; S J van Deventer
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

5.  Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production.

Authors:  P F Jørgensen; J E Wang; M Almlöf; R Solberg; C Okkenhaug; T Scholz; C Thiemermann; S J Foster; A O Aasen
Journal:  Scand J Immunol       Date:  2001-02       Impact factor: 3.487

6.  Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators.

Authors:  M D Lehner; S Morath; K S Michelsen; R R Schumann; T Hartung
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

7.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

8.  Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells.

Authors:  Masashi Ohtani; Shigenori Nagai; Shuhei Kondo; Shinta Mizuno; Kozue Nakamura; Masanobu Tanabe; Tsutomu Takeuchi; Satoshi Matsuda; Shigeo Koyasu
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

9.  Interleukin-12 production by human alveolar macrophages is controlled by the autocrine production of interleukin-10.

Authors:  P Isler; B G de Rochemonteix; F Songeon; N Boehringer; L P Nicod
Journal:  Am J Respir Cell Mol Biol       Date:  1999-02       Impact factor: 6.914

10.  Interleukin 10 protects mice from lethal endotoxemia.

Authors:  M Howard; T Muchamuel; S Andrade; S Menon
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  23 in total

Review 1.  New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

Review 2.  Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha; Daniel W Beury; Virginia K Clements
Journal:  Semin Cancer Biol       Date:  2012-02-01       Impact factor: 15.707

3.  LPS induces the degradation of programmed cell death protein 4 (PDCD4) to release Twist2, activating c-Maf transcription to promote interleukin-10 production.

Authors:  Mirjam W M van den Bosch; Eva Palsson-Mcdermott; Derek S Johnson; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2014-06-30       Impact factor: 5.157

4.  Mammalian target of rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection.

Authors:  Megan E B Foldenauer; Sharon A McClellan; Elizabeth A Berger; Linda D Hazlett
Journal:  J Immunol       Date:  2013-04-26       Impact factor: 5.422

5.  HGF signaling impacts severity of Pseudomonas aeruginosa keratitis.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald Barrett; Megan Foldenauer; Linda D Hazlett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-09       Impact factor: 4.799

6.  Receptor signaling in immune cell development and function.

Authors:  Xiao-Ping Zhong; Jinwook Shin; Balachandra K Gorentla; Tommy O'Brien; Sruti Srivatsan; Li Xu; Yong Chen; Danli Xie; Hongjie Pan
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

7.  The combination of IκB kinase β inhibitor and everolimus modulates expression of interleukin-10 in human T-cell lymphotropic virus type-1-infected T cells.

Authors:  Chie Nishioka; Takayuki Ikezoe; Jing Yang; Keiko Udaka; Akihito Yokoyama
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

8.  Porphyromonas gingivalis Outer Membrane Vesicles Induce Selective Tumor Necrosis Factor Tolerance in a Toll-Like Receptor 4- and mTOR-Dependent Manner.

Authors:  Tobias Waller; Laura Kesper; Josefine Hirschfeld; Henrik Dommisch; Johanna Kölpin; Johannes Oldenburg; Julia Uebele; Achim Hoerauf; James Deschner; Sören Jepsen; Isabelle Bekeredjian-Ding
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

9.  Rapamycin unbalances the polarization of human macrophages to M1.

Authors:  Alessia Mercalli; Ines Calavita; Erica Dugnani; Antonio Citro; Elisa Cantarelli; Rita Nano; Raffaella Melzi; Paola Maffi; Antonio Secchi; Valeria Sordi; Lorenzo Piemonti
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

Review 10.  IL-10 function, regulation, and in bacterial keratitis.

Authors:  Linda D Hazlett; Xiaoyu Jiang; Sharon A McClellan
Journal:  J Ocul Pharmacol Ther       Date:  2014-04-16       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.